Karuna Gears Up To File KarXT, A Schizophrenia ‘Gamechanger’
Free From Serious Side-Effects Of Standard Treatment
Executive Summary
New CEO Bill Meury said Karuna had plenty of time, money and physician enthusiasm to ensure a US launch in 2024 would be a success.
You may also be interested in...
Karuna Three-For-Three As Another KarXT Schizophrenia Trial Hits Primary Endpoint
The company is on track for a mid-2023 FDA filing, while executives suggested that they would likely pursue partnership for commercialization of the drug in Europe.
Biopharma Funding Contracted Last Year – And 2023 Will See The Squeeze Continue
Now the pandemic-era biotech boom is over, biopharma companies and investors are both adjusting their financing strategies to survive and even thrive in the new environment.
New Era For Schizophrenia Therapy Beckons As Karuna Soars On Promising Phase III Data
The PureTech Health-founded entity believes it has made a significant step forward in the treatment of schizophrenia with its muscarinic-receptor acting agent KarXT, which could offer a completely new way to address all three symptom domains of the disease.